In:
European Journal of Haematology, Wiley, Vol. 109, No. 6 ( 2022-12), p. 749-754
Kurzfassung:
Despite the effectiveness of newer drugs for the treatment of multiple myeloma (MM), the outcomes are further improved by subsequent autologous stem cell transplantation (ASCT). Data on effectiveness in older patients are limited. We compared outcomes in patients aged 65–75 years depending on whether they were treated with ASCT or not and compared those to outcomes in patients 〈 65 years. Methods This was a retrospective, single‐center study. We compared progression‐free survival (PFS) and overall survival (OS) for all MM patients below and above the age of 65 years treated ± ASCT at the Karolinska University Hospital between 2010 and 2020. PFS and OS were calculated by the Kaplan–Meier method. Variables affecting PFS and OS were evaluated using Cox regression model. Results Both PFS and OS were improved in the group 65–75 years treated +ASCT compared to those treated pharmacologically ( p = 0.008 and p 〈 0.001, respectively). There were no significant differences between patients 〈 65 years and those 65–75 years treated with ASCT. Conclusion The findings indicate that even patients 〉 65 years should be evaluated as candidates for ASCT. An individualized approach supported by a frailty/geriatric assessment score could assist clinicians to select the appropriate treatment for each patient.
Materialart:
Online-Ressource
ISSN:
0902-4441
,
1600-0609
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2022
ZDB Id:
2027114-1
